VEGFA and fatty liver disease: While silencing of FABP1 directly ameliorates hepatic steatosis (Mukai et al., 2017), its effect on HCC development seems to depend more on increased secretion of vascular endothelial growth factor-A (VEGF-A) (Ku et al., 2016), therefore promoting angiogenesis.